Search

© 2017 Elsevier B.V. The Agilent Chip Cube Interface is a microfluidic chip-based technology originally designed for nanospray molecular mass spectrometry in which the sample enrichment, nano-column, tubing, connectors and spray tip were integrated into a single biocompatible chip. Here we describe the hyphenation of the Chip Cube Interface to ICP-MS via modification of the standard HPLC chip design and a new total consumption nebuliser suitable for flow rates as low as 300 nL min−1. The potential of the instrument to eliminate common nanoLC – ICP-MS shortcomings such as leaks, blockages and band-broadening was demonstrated via analysis of cyanocobalamin in equine plasma. The method was linear over three orders of magnitude with an r2 of 0.9999, the peak area repeatability was 1.9% (n = 7), and the detection limit was 14 ng mL−1. This novel configuration of the Chip Cube Interface coupled to ICP-MS is a suitable platform for the analysis of biomolecules associated with trace metals and speciation applications.

Monoclonal antibodies (mAb), therapeutic proteins for treatments of cancers and immunological diseases, need detailed structural elucidation and improved analytics because of their biopharmaceutical presence. Inherently heterogeneous proteins, mAbs have various protein modifications, and the most important modification for these large glycoproteins is N-glycosylation on their Fc region. In this work, we compare several quantitative techniques; including microfluidic based on-line deglycosylation and integrated nanoLC/MS analysis of the released glycans, nanoLC/MS analysis of intact glycoprotein and/or glycoprotein fragments, as well as UHPLC-FLD analysis of off-line released derivatized glycans.

The sheer complexity of the Bible and of its interpretation pushed the technologies of the page to their limits, as authors ... For nearly every early modern English reader, from those who got little further than the Lord's Prayer on their hornbooks...